©2024 Stanford Medicine
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Not Recruiting
Trial ID: NCT03859700
Purpose
Open-label, follow-up study for subjects who completed the EPITOPE study.
Official Title
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children
Stanford Investigator(s)
Sayantani Sindher
Clinical Associate Professor, Medicine Clinical Associate Professor, Pediatrics - Allergy and Clinical Immunology
Eligibility
Inclusion Criteria:
- completion of the EPITOPE study
Exclusion Criteria:
- Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled
generalized active eczema, ichthyosis vulgaris) extending widely on the skin and
especially on the back or arms with no intact zones to apply the Viaskin patches.
- Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma
Intervention(s):
biological: DBV712 250 mcg
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305